Drug intelligence / Profile preview

diphtheria vaccine (low-dose) Biomed-Lublin

Development stage
Approved
Lead developer
Biomed-Lublin
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular, Subcutaneous
01

Overview

The diphtheria vaccine (low-dose) from Biomed-Lublin, often referred to by the shorthand 'd', is a monovalent vaccine containing a reduced dose of purified diphtheria toxoid. It is specifically designed for booster immunization against diphtheria in older children, adolescents, and adults who have previously completed a primary vaccination series. The vaccine is produced by inactivating the toxin from *Corynebacterium diphtheriae* with formaldehyde and adsorbing it onto an aluminum adjuvant to enhance immunogenicity. The use of a low-dose formulation (indicated by the lowercase 'd' in vaccine nomenclature) is intended to maintain protective antibody levels while minimizing the risk of local and systemic hypersensitivity reactions that are more common in older populations with pre-existing immunity.

Brand names
d
Other names
diphtheria toxoid (low-dose)adsorbed diphtheria vaccine (low-dose)Szczepionka błonicza adsorbowana d
02

Targets

Diphtheria toxin

Beyond the preview

Go deeper on diphtheria vaccine (low-dose) Biomed-Lublin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diphtheria vaccine (low-dose) Biomed-Lublin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call